Experimental investigations indicate that Dihexa interacts with the hepatocyte growth factor (HGF)/c-Met signaling system through modulation of HGF-associated molecular interactions rather than direct activation of the c-Met receptor.

Research has examined its influence on HGF-dependent signaling processes, receptor-mediated signal transduction, and downstream regulatory pathways associated with c-Met activation. This mechanism makes Dihexa a valuable tool for studies of HGF/c-Met pharmacology, growth factor signaling, and receptor-associated regulatory networks.

Published experimental investigations have reported effects of Dihexa on signaling pathways associated with synaptic structure, dendritic architecture regulation, and receptor-mediated mechanisms involved in synaptogenesis.

These findings have generated significant research interest in the compound as a tool for investigating HGF/c-Met-associated signaling networks, synaptic regulatory processes, and molecular pathways governing neuronal connectivity. Continued mechanistic investigation remains an active area of research.

Dihexa was developed as a structurally modified analogue of angiotensin IV and retains key features of the parent scaffold while incorporating modifications designed to alter physicochemical and pharmacological properties. This structural relationship has made Dihexa useful for comparative investigations of angiotensin-derived compounds, structure-activity relationships, peptide-derived signaling modulators, and the molecular determinants governing receptor-associated signaling pathways.